Search results for "Central Nervous System Neoplasm"

showing 10 items of 31 documents

Risk factors for central nervous system tumors in children: New findings from a case-control study

2017

BACKGROUND: Central nervous system tumors (CNS) are the most frequent solid tumor in children. Causes of CNS tumors are mainly unknown and only 5% of the cases can be explained by genetic predisposition. We studied the effects of environmental exposure on the incidence of CNS tumors in children by subtype, according to exposure to industrial and/or urban environment, exposure to crops and according to socio-economic status of the child. METHODS: We carried out a population-based case-control study of CNS tumors in Spain, covering 714 incident cases collected from the Spanish Registry of Childhood Tumors (period 1996-2011) and 4284 controls, individually matched by year of birth, sex, and au…

Central Nervous SystemMaleUrban PopulationSocial Scienceslcsh:MedicineNervous SystemUrban EnvironmentsCentral Nervous System NeoplasmsFamilies0302 clinical medicineSociologyRisk FactorsEpidemiology of cancerMedicine and Health SciencesMedicine030212 general & internal medicinelcsh:ScienceChildNeurological TumorsChildrenGeographic AreasAir PollutantsMultidisciplinaryGeographyAgricultureGliomaPlantsTerrestrial EnvironmentsOncologyNeurology030220 oncology & carcinogenesisChild PreschoolFemaleAnatomyInfantsResearch ArticleUrban Areasmedicine.medical_specialtyAdolescentCropsAstrocytomaFruits03 medical and health sciencesHumansSocial StratificationPesticidesSistema nerviós centralbusiness.industryEcology and Environmental Scienceslcsh:ROrganismsCase-control studyInfant NewbornBiology and Life SciencesCancers and NeoplasmsCancerInfantEnvironmental Exposuremedicine.diseaseSocial ClassAge GroupsCentral nervous systemFamily medicineCase-Control StudiesPeople and PlacesEarth SciencesPopulation Groupingslcsh:QbusinessCrop Science
researchProduct

Tumors of the central nervous system in children and adolescents.

2011

Multimodal treatment approaches for children with tumors of the central nervous system (CNS) have markedly contributed to improved survival. Before 1970, the survival rate among children with medulloblastoma, the most common malignant CNS tumor in children, was about 20%. At present, in contrast, cure can be achieved in more than 75% of children with a favorable constellation of risk factors. In this review article for clinicians, we give an overview of the current understanding of the pathology, presenting manifestations, early diagnosis, and treatment of CNS tumors in children and adolescents.We report the research findings of the German Treatment Network "HIT" and selectively review the …

Diagnostic ImagingMalePediatricsmedicine.medical_specialtyAdolescentIntracranial PressureQuality Assurance Health CareCentral nervous systemImproved survivalReview ArticleCentral Nervous System NeoplasmsGermanymedicineMultimodal treatmentHumansNeoplasm InvasivenessCNS TUMORSChildSurvival rateNeoplasm StagingMedulloblastomabusiness.industryInfantGeneral Medicinemedicine.diseasePrognosisCombined Modality TherapyReview articlemedicine.anatomical_structureTreatment OutcomeChild PreschoolImmunologyFemaleNeoplasm GradingMalignant CNS TumorbusinessFollow-Up StudiesDeutsches Arzteblatt international
researchProduct

Up-to-date monitoring of childhood cancer long-term survival in Europe: central nervous system tumours.

2007

ABSTRACT Background Tumours of the central nervous system (CNS) account for 15–20% of all malignant childhood tumours in developed countries. Steady improvement of survival of children with CNS tumours has been reported for the past decades. However, these results, obtained by cohort analysis of survival, do not reflect the full extent of recent improvement. Methods Using selected registries from the database of the Automated Childhood Cancer Information System (ACCIS), we calculated period survival estimates for the years 1995–99 for children diagnosed with a malignant CNS tumour. Results The overall 10-year period survival estimate for the years 1995–99 was 59% for children with all CNS t…

EpendymomaPediatricsmedicine.medical_specialtyAdolescentCentral nervous systemAstrocytomaCentral Nervous System NeoplasmsmedicineHumansNeuroectodermal Tumors PrimitiveChildbusiness.industryAge FactorsInfant NewbornAstrocytomaCancerInfantHematologymedicine.diseasePrognosisEuropemedicine.anatomical_structureOncologyEl NiñoEpendymomaChild PreschoolCohortbusinessDeveloped countryCohort studyAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Early deaths from childhood cancer in Germany 1980-2016

2020

Abstract Background Even though the survival of childhood cancer has improved over the last decades, there are still children dying shortly after diagnosis. The aim of the study is to add to understanding of the reasons for deaths shortly after date of diagnosis. Methods Using data of the population-based German Childhood Cancer Registry (cancer below 15 years of age diagnosed between 1980 and 2016), we compared characteristics of 671 children with cancer who died within 30 days of diagnosis to 53,649 patients with childhood cancer who survived longer. In addition to a descriptive analysis, we used logistic regression with multivariable fractional polynomials to describe the relationship be…

MaleCancer ResearchPediatricsmedicine.medical_specialtyAdolescentEpidemiologyPopulationMedizinLower riskCentral Nervous System Neoplasms03 medical and health sciences0302 clinical medicineRisk FactorsGermanyNeoplasmsEpidemiologyHumansMedicineRegistries030212 general & internal medicineChildeducationeducation.field_of_studyChildhood Cancer Registrybusiness.industryInfantCancerOdds ratioPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseConfidence intervalLeukemia Myeloid AcuteOncologyChild Preschool030220 oncology & carcinogenesisPopulation studyFemalebusiness
researchProduct

Temporal trends in the incidence rate of childhood cancer in Germany 1987-2004.

2007

The German Childhood Cancer Registry regularly presents graphs of childhood cancer incidence rates by period, but no systematic analysis. The Automated Childhood Cancer Information System-project found an increasing trend in Europe. Against this background we present the first detailed trend analysis of childhood (aged under 15) malignancies in Germany. We examined incidence rates separately in western Germany 1987-2004 and eastern Germany 1991-2004. We analyzed all malignancies, all main diagnostic groups and relevant subsets using an age-period-cohort model. Additionally we fitted fractional polynomials to assess the linearity of the drift. All malignancies combined (excluding Central Ner…

MaleCancer ResearchPediatricsmedicine.medical_specialtyAdolescentLymphomaCentral Nervous System NeoplasmsGermanyNeoplasmsEpidemiologymedicineHumansRegistriesChildChildhood Cancer RegistryLeukemiabusiness.industryIncidence (epidemiology)IncidenceGermany WestCancerPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseTrend analysisOncologyEl NiñoCohort effectChild PreschoolFemaleGermany EastGerm cell tumorsbusinessInternational journal of cancer
researchProduct

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

2017

Leukemia : normal and malignant hemopoiesis 31(4), 846-852 (2017). doi:10.1038/leu.2016.334

MaleCancer Researchmedicine.medical_specialtyLymphomaPopulationMedizinProcarbazineGastroenterologyCentral Nervous System Neoplasms03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansImmunologic FactorseducationAgedNeoplasm StagingProportional Hazards ModelsAged 80 and overeducation.field_of_studyHematologybusiness.industryRemission InductionPrimary central nervous system lymphomaHematologyLomustinemedicine.diseaseSurgeryTumor BurdenMethotrexateTreatment OutcomeOncology030220 oncology & carcinogenesisCytarabineQuality of LifeMethotrexateRituximabOriginal ArticleFemalebusiness030215 immunologymedicine.drugLeukemia
researchProduct

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the firs…

2016

BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma. We report the results of the first randomisation in this Article.METHODS: For the international randomised phase 2 International Extranodal Lymphoma Study Group-32 …

MaleComparative Effectiveness ResearchTransplantation ConditioningGastrointestinal DiseasesDenmarkMedizinKaplan-Meier EstimateDexamethasoneCentral Nervous System NeoplasmsDeath Sudden0302 clinical medicineIntraocular LymphomaGermanyAntineoplastic Combined Chemotherapy ProtocolsMedicineStandard treatmentOptic Nerve NeoplasmsPoisoningRemission InductionCytarabineHematopoietic Stem Cell TransplantationAnemiaHematologyInduction ChemotherapyAcute Kidney InjuryMiddle AgedCombined Modality TherapyMagnetic Resonance Imaging3. Good healthStrokeTreatment OutcomeTolerabilityItaly030220 oncology & carcinogenesischemoimmunotherapyRituximabFemaleNeurotoxicity SyndromesChemical and Drug Induced Liver InjuryRituximabSwitzerlandmedicine.drugMucositismedicine.medical_specialtyLymphoma B-CellNeutropeniaThioTEPAInfectionsTransplantation AutologousDisease-Free Survival03 medical and health sciencesprimary CNS lymphomaChemoimmunotherapyInternal medicineJournal Articleprimary CNS lymphoma chemoimmunotherapyHumansbusiness.industryThrombosismedicine.diseaseThrombocytopeniaUnited KingdomSurgeryTransplantationRegimenMethotrexateHeart InjuriesHyperglycemiaRadiotherapy Adjuvantbusiness030217 neurology & neurosurgeryFebrile neutropeniaThiotepaFollow-Up StudiesThe Lancet. Haematology
researchProduct

Childhood central nervous system tumours – incidence and survival in Europe (1978–1997): Report from Automated Childhood Cancer Information System pr…

2006

Abstract This paper describes the incidence and survival of childhood central nervous system (CNS) tumours in Europe for the period 1978–1997. A total of 19,531 cases, aged 0–14 years, from the ACCIS database were analysed by five regions: the British Isles, East, North, South, and West. Overall age-standardised incidence rate (ASR) of CNS tumours in Europe (1988–1997) was 29.9 per million, with the highest rates in the North. Astrocytoma (ASR = 11.8), primitive neuroectodermal tumours (PNET) (ASR = 6.5) and ependymoma (ASR = 3.4) were the most frequent types. Incidence increased significantly during 1978–1997, on average by 1.7% per year. Diagnostic methods may partially explain incidence …

MaleEpendymomaCancer Researchmedicine.medical_specialtyAdolescentDatabases FactualChildhood cancerCentral nervous systemCentral Nervous System NeoplasmsEpidemiologymedicineHumansRegistriesChildcentral nervous system tumoursbusiness.industryIncidenceIncidence (epidemiology)Infant NewbornInfantChildhood cancers - survival - time trends; central nervous system tumoursAstrocytomaCancermedicine.diseaseSurvival AnalysisSurgeryEuropemedicine.anatomical_structureOncologyEl NiñoChild PreschoolFemalebusinessChildhood cancers - survival - time trendsDemographyEuropean Journal of Cancer
researchProduct

Synthesis and antiproliferative activity of [1,2,3,5]tetrazino[5,4-a]indoles, a new class of azolo-tetrazinones.

2004

Eight derivatives of the new ring system [1,2,3,5]tetrazino[5,4-a]indole-4-one 7, were synthesised in good yields by reaction of 2-diazoindoles with alkyl or aryl isocyanates. Compounds 7 were screened at National Cancer Institute (NCI) for their activity against a panel of approximately 60 human tumour cell lines. Some of them showed antiproliferative activity having generally GI50 in the micromolar range. The most sensitive cell lines were SF-295, SNB-75 and SF-539 of the CNS cancer sub-panel, SR of the leukaemia sub-panel, UACC-62 of the melanoma sub-panel and OVCAR-4 of the ovarian cancer sub-panel. 2004 Elsevier Ltd. All rights reserved.

MaleIndolesStereochemistryClinical BiochemistryPharmaceutical ScienceAntineoplastic AgentsBreast NeoplasmsBiochemistryChemical synthesisCentral Nervous System Neoplasmschemistry.chemical_compoundCarcinoma Non-Small-Cell LungCell Line TumorDrug DiscoverymedicineHumansMolecular BiologyMelanomaOvarian NeoplasmsLeukemiaMolecular StructureArylMelanomaOrganic ChemistryCancerDiazoindoles Azolotetrazinones Antiproliferative activity Tetrazino-indolesmedicine.diseaseIn vitroSensitive cellchemistryCell cultureColonic NeoplasmsMolecular MedicineFemaleDrug Screening Assays AntitumorOvarian cancerBioorganicmedicinal chemistry
researchProduct

Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma

2015

Objective: This is the final report of a phase III randomized study to evaluate whole-brain radiotherapy (WBRT) in primary therapy of primary CNS lymphoma (PCNSL) after a median follow-up of 81.2 months. Methods: Patients with newly diagnosed PCNSL were randomized to high-dose methotrexate (HDMTX)–based chemotherapy alone or followed by WBRT. We hypothesized that the omission of WBRT would not compromise overall survival (OS; primary endpoint), using a noninferiority design with a margin of 0.9. Results: In the per-protocol population (n = 320), WBRT nonsignificantly prolonged progression-free survival (PFS) (median 18.2 vs 11.9 months, hazard ratio [HR] 0.83 [95% confidence interval (CI) 0…

MaleOncologyAntimetabolites Antineoplasticmedicine.medical_specialtyLymphomamedicine.medical_treatmentPopulationMedizin610 Medicine & healthDisease-Free Survivallaw.inventionCentral Nervous System NeoplasmsRandomized controlled triallawInternal medicinemedicineClinical endpointHumanseducationAgededucation.field_of_studyChemotherapybusiness.industryHazard ratioAntineoplastic ProtocolsMiddle AgedCombined Modality TherapyConfidence interval10040 Clinic for NeurologyRadiation therapyMethotrexateTreatment Outcome2728 Neurology (clinical)MethotrexateNeurology (clinical)Cranial Irradiationbusinessmedicine.drug
researchProduct